Did Priority Review Just Shift Agios Pharmaceuticals’ (AGIO) Investment Narrative?By AdminBitOctober 21, 20260 Agios Pharmaceuticals is pursuing US FDA accelerated approval for mitapivat in sickle cell disease after Priority Review of Phase 3 RISE UP data showing significant hemoglobin responses in patients aged 16 and older.
